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first characterized the term graft-versus-host disease (GVHD) in mice in 1957. Acute GVHD is a distinct syndrome, which involves the development of dermatitis (skin rash), gastroenteritis (diarrhea, abdominal pain) and hepatitis (jaundice) within the first 100 days after an allogeneic bone marrow transplant. Chronic GVHD usually presents as a diverse multiorgan symptom complex developing after the first 100 days of transplant. GVHD remains a major complication of clinical bone marrow transplantation (BMT). The incidence of GVHD ranges from 10 to 80% depending on the degree of donor-recipient histocompatibility, number of transplanted T cells, patient age and GVHD prophylactic regimen. 2 GVHD has been reported to occur rarely in animals and humans undergoing identical twin (syngeneic) or autologous transplant. [3] [4] [5] [6] Hood et al 7 presented clinical and histologic evidence of mild selflimiting cutaneous GVHD in 8% of their patients who had undergone syngeneic or autologous transplant. Reports of severe GVHD development after syngeneic bone marrow transplant are becoming more frequent. [8] [9] [10] [11] We also report two cases of severe syngeneic graft-versus-host disease (SGVHD) requiring high-dose steroids and immunosuppressive therapy.
Case 1
A 43-year-old Caucasian male presented with left axillary lymphadenopathy. An excisional biopsy of the left cervical lymph node showed follicle center lymphoma, follicular and diffuse, grade III. He received six cycles of CHOP chemotherapy and had achieved a complete remission. At 4-month follow-up, a CT scan showed progression of mesenteric and retroperitoneal lymphadenopathy, which later became symptomatic. A biopsy of a left paraaortic lymph node revealed diffuse large B-cell lymphoma. He had complete symptom resolution from two cycles of salvage chemotherapy with dexamethasone, highdose cytarabine and cisplatin. He then underwent a syngeneic stem cell transplant from an HLA-identical triplet. His transplant preparative regimen consisted of busulfan, etoposide and cyclophosphamide. On day +8 he developed a generalized, erythematous maculopapular rash on his face, neck and upper chest. This was accompanied by profuse watery diarrhea. He achieved an absolute neutrophil count of 4500/ml on posttransplant day 9. Investigations for a possible infectious etiology were unrevealing. Sigmoidoscopy showed patchy erythema of the colon. The biopsy of sigmoid colon was consistent with GVHD grade IV showing marked mucosal necrosis with focal regenerative epithelial changes ( Figure 1 ). Immunohistochemical staining was negative for CMV. RFLP analysis performed pretransplant showed that both donor and recipient had identical alleles at four different loci tested; the same pattern was observed in the recipient's peripheral blood at day +30. He was treated with high-dose steroids, cyclosporine A, prophylactic antibiotics and total parenteral nutrition. He responded well to the treatment but symptoms recurred after 3 months upon tapering his immunosuppression requiring the reinstitution of steroids. Several attempts to discontinue immunosuppressive therapy failed due to the exacerbation of SGVHD symptoms. Finally, immunosuppressive therapy was totally discontinued on day +303 following complete resolution of symptoms. Unfortunately, 3 months after the disappearance of clinical SGVHD, his non-Hodgkin's lymphoma relapsed.
Case 2
A 40-year-old Caucasian man was diagnosed with acute myeloid leukemia after a 4-week history of fevers, night sweats, weight loss and leukocytosis. He received cytarabine and idarubicin as induction therapy and achieved a complete remission. His consolidation therapy consisted of cytarabine and intrathecal methotrexate. He underwent a syngeneic stem cell transplant from his identical twin (as determined by HLA matching and VNTR analysis). His transplant preparative regimen contained high-dose busulfan, etoposide and cyclophosphamide. He tolerated the high-dose chemotherapy and stem cell infusion with no problems and his absolute neutrophil count reached 4500/ ml on post-transplant day +10. He developed a generalized erythematous maculopapular rash on his neck, shoulders, upper arms and chest on day +8. Profuse watery diarrhea (up to 4 liters of stool/day) occurred on day +10. Investigations for a possible infectious etiology were negative. An EGD and colonoscopy on day +13 revealed severe duodenitis and nonspecific colitis. Biopsies of the duodenum and terminal ileum showed confluent loss of epithelial cells within the mucosa. The colon biopsies had more intact mucosa with easily identifiable apoptotic bodies compatible with acute GVHD (Figure 2 ). He was treated with high-dose steroids, cyclosporine A, total parentral nutrition and prophylactic antibiotics. He responded very well to the treatment, and immunosuppressive therapy was successfully tapered off on day +70 after complete resolution of his GVHD symptoms. He relapsed after 17 months from his initial syngeneic bone marrow transplant.
Discussion
In 1966, Billingham 12 hypothesized that the development of GVHD required the transfer of immunologically competent cells to a host that must be incapable of mounting an effective response to destroy the transplanted cells (ie an immunocompromised host). Another essential requisite was the capability of the host to express the tissue antigen that is not present in the transplant donor cells. 12 The human major histocompatibility complex (MHC) contains multiple genes including those encoding class I and class II antigenic molecules of the HLA system. The HLA system plays a vital role in antigen presentation to the immunocompetent cell. The degree of histocompatibility at the MHC complex (HLA encoding loci) theoretically determines the severity of GVHD. The proposed mechanism for the development of GVHD can be divided into two phases. An afferent phase starting prior to transplant during the conditioning regimen consists of antigen presentation, Tcell activation, clonal expansion and differentiation. Dysregulated release of cytokines during the conditioning may upregulate adhesion molecules and enhance the expression of recipient MHC antigens. Antigen presenting cells express cell-surface peptides bound to the HLA molecule (both class I and class II). The mature donor T cells recognize the recipient peptide-HLA complex, in which either the HLA molecule or the peptide (so-called minor histocompatability antigens) is foreign to the T cells. This leads to the activation of T cells and release of different cytokines. These cytokines, through their autocrine and paracrine effects, cause clonal expansion and differentiation of T cells. The efferent phase, although less well understood, seems to consist of the dysregulated release of lymphokines causing cell injury manifested as GVHD. 13 Patients receiving autologous or syngeneic BMT should not theoretically have a trigger to initiate GVHD. Nevertheless, Sale et al 14 noticed the histologic changes consistent with grade II cutaneous GVHD in the skin biopsies of their control population which received a syngeneic or autologous transplant. Rappeport et al 5 first reported the clinical syndrome of GVHD in syngeneic bone marrow According to one theory, the emerging reports of SGVHD in autologous and syngeneic transplant patients suggest a revision of Billingham's postulates, to include the inappropriate recognition of the host self-antigen by immunocompetent T cells. 13 The graft-versus-host reaction in syngeneic bone marrow transplant patients appears to be mediated by autoreactive lymphocytes directed at MHC class II protein. 3 These autoreactive cells are thought to develop in a damaged thymic medulla, which lacks the cells bearing the MHC class II antigens. When these autoreactive cells migrate to the periphery, their activation takes place via the antigen presenting cells bearing the MHC class II antigens foreign to these cells. This ultimately mediates damage to target organs by releasing cytokines causing SGVHD. The counter-regulatory lymphocytes that would normally inactivate and eliminate these autoreactive cells have themselves been eliminated in an immunocompromised host either because of the conditioning regimen, radiation or cyclosporine A. Most of the initial reports of GVHD in recipients of syngeneic and autologous transplants were linked to cyclosporine A therapy. Glazier et al 15 have demonstrated the development of GVHD in lethally irradiated rats after discontinuing cyclosporine A during the period of immune reconstitution. The mechanism by ALL ¼ acute lymphoblastic leukemia; AML ¼ acute myeloid leukemia; CML ¼ chronic myelocytic leukemia; CR ¼ complete remission; ER ¼ early relapse; ANLL ¼ acute non-lymphoblastic leukemia; CLL ¼ chronic lymphocytic leukemia; NHL ¼ non-Hodgkin's lymphoma; CSA ¼ cyclosporine A; Thal ¼ thalidomide; HUS ¼ hemolytic uremic syndrome; +-+++ ¼ continuum of severity. a Cytarabine 500 mg/m/day on day À13 to À8, cyclophosphamide 60 mg/kg/day on day À3, and À2, total body irradiation 800-900 rad on day À1. b Cyclophosphamide 60 mg/kg/day on day À5, À4, total body irradiation 1000 rad. c Dose not reported. d Cyclophosphamide Â 2 60 mg/kg/day on day À5, À4. e Total body irradiation 1000 rad with lung shielding.
f Total body irradiation 1200 rad twice/day for 3 days. g Melphalan 180 mg/m 2 day À1. h Cyclophosphamide 50 mg/kg/day Â 4 days. i Busulfan 8 mg/kg Â 4 days, cyclophosphamide 30 mg/kg/day Â 2 days, total body irradiation 12 Gy in 6 Â 2 Gy fractions in 2 days. j Cyclophosphamide 120 mg/kg, total body irradiation 750 cGy. k Busulfan 1 mg/kg Â 16 doses, cyclophosphamide 60 mg/kg/day Â 2 days, cyclosporine A 1 mg/kg from day 1. l Busulfan 4 mg/kg Â 4 days, cyclophosphamide 60 mg/kg/day Â 2 days. m Busulfan 1 mg/kg Â 14 doses, cyclophosphamide 60 mg/kg/day Â 2 days, etoposide 60 mg/kg Â 2 days. which SGVHD develops in cyclosporine A-treated patients is not yet fully understood. Cyclosporine A enhances the escape of T cells from the usual negative selection by inhibiting clonal deletion mechanisms in the thymus leading to the release of autoreactive cells. 16, 17 It is postulated that cyclosporine A reduces the class II antigenic expression in the thymus, and thus the maturing immune system fails to recognize the class II antigen as self. 3, 18 These autoreactive cells are capable of mediating an immune response upon exposure to the MHC class II antigens in the periphery. Cyclosporine A also prevents the re-establishment of regulatory lymphocytes that would normally prevent the autoreactivity.
Cyclosporine A was not used in either of our cases. This suggests that other mechanisms may exist for stimulating the recognition of self-antigens in order for SGVHD to develop. Damage to host tissue during transplant conditioning results in release of inflammatory cytokines including interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a). Activation of both the alloreactive and autoreactive cells by these cytokines has been observed in many studies. 19, 20 Many researchers have suggested the possibility of viral infections triggering or promoting the syngeneic GVHD-like syndrome. This is based on evidence of seroconversion or reactivation of CMV, HSV, mumps or hepatitis B virus in some of the patients developing SGVHD that lack the characteristic findings present in those infections. 4, 7 Viral infection may alter a recipient's self-antigen(s) so that they are recognized by donor lymphocytes as foreign, thus initiating an autoimmune reaction. 21 We considered the possibility that our patients had transfusion-associated graft-versus-host disease (TAGVHD). However, we believe that TAGVHD is not likely in our patients. They received only irradiated blood products, which decreases the likelihood of TAGVHD to almost 0% (only one reported case of TAGVHD has been identified in patients receiving irradiated blood products). 22 Secondly, TAGVHD is usually severe, results in pancytopenia (secondary to marrow aplasia) and is almost always fatal despite immunosuppressive therapy. 23 Peripheral blood chimerism analysis performed in patient 1 while he had active disease showed no evidence of third-party engraftment. Although chimerism analysis was not available for patient 2 when signs and symptoms of GVHD were present, his subsequent clinical course is inconsistent with third-party engraftment. Viral infections such as CMV or hepatitis can give rise to similar syndromes; however, in our cases microbiological, serological and histological evidences, as well as DNA PCR analysis, were negative. This essentially excludes infections as a likely cause of symptoms in our patients.
It is intriguing to note that the patient with nonHodgkin's lymphoma relapsed soon after the disappearance of SGVHD. This might represent the loss of graftversus-tumor effect associated with SGVHD. It has been shown that patients undergoing autologous bone marrow transplant and induction of GVHD with cyclosporine A exhibit specific cytotoxic T cells directed against Ia (MHC class II antigen) that appear with the onset of disease and are no longer detected after the resolution of GVHD manifestations. 24 Lymphocytes harvested at the time of development of autologous GVHD showed in vitro cytotoxic activity against a variety of tumor cell targets. 24, 25 More recently, cyclosporine A has been used to intentionally elicit GVHD in recipients of autologous transplants in an effort to obtain a graft-versus-tumor effect against their malignancy.
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Conclusions SGVHD is a well-reported phenomenon that may not be as rare as once thought. The graft-versus-host reaction (GVHR) in syngeneic bone marrow transplant patients appears to be mediated by autoreactive lymphocytes directed at the MHC class II proteins. SGVHD should be considered in the differential diagnosis of rash or diarrhea at the time of engraftment in identical twin bone marrow transplants. Prompt institution of immuno-suppressive therapy may reduce the associated morbidity of this clinical syndrome.
